In addition, beneficial effects of pharmacological FXR stimulation have also been demonstrated in clinical trials: Obeticholic acid (OCA) treatment has been shown to exert positive effects in patients with primary biliary cholangitis (PBC) [6,7,8] and is now approved by the FDA and EMA for the treatment of PBC in patients that have an incomplete response or are intolerant to UDCA [9]. Here, NR1H4 is linked to primary biliary cholangitis.